163 related articles for article (PubMed ID: 26476625)
1. Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings-a meta-analysis.
Jordan K; Warr DG; Hinke A; Sun L; Hesketh PJ
Support Care Cancer; 2016 May; 24(5):1941-1954. PubMed ID: 26476625
[TBL] [Abstract][Full Text] [Related]
2. Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review.
Jordan K; Jahn F; Aapro M
Ann Oncol; 2015 Jun; 26(6):1081-1090. PubMed ID: 25755107
[TBL] [Abstract][Full Text] [Related]
3. Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis.
Zhang Z; Zhang Y; Chen G; Hong S; Yang Y; Fang W; Luo F; Chen X; Ma Y; Zhao Y; Zhan J; Xue C; Hou X; Zhou T; Ma S; Gao F; Huang Y; Chen L; Zhou N; Zhao H; Zhang L
Oncologist; 2018 May; 23(5):603-616. PubMed ID: 29330211
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Olanzapine for the Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Meena JP; Gupta AK; Jat KR; Anandani G; Sasidharan A; Tanwar P
J Pediatr Hematol Oncol; 2023 Oct; 45(7):361-369. PubMed ID: 37539996
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of 5HT3RA, DEX, and NK1RA for the prevention of FOLFIRINOX-induced nausea and vomiting in patients with pancreatic cancer: a retrospective cohort study.
Hishida-Sadaka S; Iihara H; Ohata K; Matsuoka S; Watanabe D; Iwashita T; Uemura S; Shimizu M; Suzuki A
Support Care Cancer; 2023 Oct; 31(12):657. PubMed ID: 37884842
[TBL] [Abstract][Full Text] [Related]
6. Adherence to antiemetic guidelines in solid cancer patients receiving highly emetogenic chemotherapy in Korea.
Lee R; Ku M; Je NK
Support Care Cancer; 2024 Feb; 32(3):190. PubMed ID: 38400861
[TBL] [Abstract][Full Text] [Related]
7. 2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents.
Scotté F; Schwartzberg L; Iihara H; Aapro M; Gralla R; Hesketh PJ; Jordan K; Chow R; Herrstedt J
Support Care Cancer; 2023 Dec; 32(1):45. PubMed ID: 38114821
[TBL] [Abstract][Full Text] [Related]
8. Pooled Analysis of Studies Evaluating Fosnetupitant and Risk Factors for Cisplatin-Induced Nausea and Vomiting During the Extended Overall Phase.
Inui N; Toi Y; Yoneshima Y; Morise M; Hata A; Kubota K; Saeki T; Tamura T
Adv Ther; 2023 Nov; 40(11):4928-4944. PubMed ID: 37715851
[TBL] [Abstract][Full Text] [Related]
9. A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting.
Wang XF; Feng Y; Chen Y; Gao BL; Han BH
Sci Rep; 2014 Apr; 4():4813. PubMed ID: 24770591
[TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of real-world prescribing data for managing cisplatin-based chemotherapy-induced nausea and vomiting in China.
Si X; Zhang H; Ding Q; Liu G; Huang L; Sun X
Cancer Med; 2024 Mar; 13(6):e7121. PubMed ID: 38515309
[TBL] [Abstract][Full Text] [Related]
11. Prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients: A clinical practice guideline.
Patel P; Robinson PD; Cohen M; Devine K; Gibson P; Holdsworth MT; Neumann E; Orsey A; Phillips R; Spinelli D; Thackray J; van de Wetering M; Woods D; Cabral S; Sung L; Dupuis LL
Pediatr Blood Cancer; 2022 Dec; 69(12):e30001. PubMed ID: 36221901
[TBL] [Abstract][Full Text] [Related]
12. Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk.
Shimokawa M; Hayashi T; Nishimura J; Satoh T; Fukunaga M; Matsui R; Tsuji Y; Mizuki F; Kogawa T
BMC Cancer; 2021 Oct; 21(1):1111. PubMed ID: 34656107
[TBL] [Abstract][Full Text] [Related]
13. Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV).
Rashad N; Abdel-Rahman O
Drug Des Devel Ther; 2017; 11():947-954. PubMed ID: 28392676
[TBL] [Abstract][Full Text] [Related]
14. Neiguan (PC6) acupoint stimulation for preventing chemotherapy-induced nausea and vomiting: a cost-effective supplement in guideline-inconsistent chemotherapy-induced nausea and vomiting prophylaxis subgroup.
Wenxi YU; Lina T; Hongtao LI; Yonggang W; Zan S
J Tradit Chin Med; 2024 Jun; 44(3):581-585. PubMed ID: 38767643
[TBL] [Abstract][Full Text] [Related]
15. 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents.
Herrstedt J; Celio L; Hesketh PJ; Zhang L; Navari R; Chan A; Saito M; Chow R; Aapro M
Support Care Cancer; 2023 Dec; 32(1):47. PubMed ID: 38127246
[TBL] [Abstract][Full Text] [Related]
16. Resource Utilization for Chemotherapy-Induced Nausea and Vomiting Events in Patients with Solid Tumors Treated with Antiemetic Regimens.
Schwartzberg L; Harrow B; Lal LS; Radtchenko J; Lyman GH
Am Health Drug Benefits; 2015; 8(5):273-82. PubMed ID: 26380034
[TBL] [Abstract][Full Text] [Related]
17. Investigating racial disparities in use of NK1 receptor antagonists to prevent chemotherapy-induced nausea and vomiting among women with breast cancer.
Check DK; Reeder-Hayes KE; Basch EM; Zullig LL; Weinberger M; Dusetzina SB
Breast Cancer Res Treat; 2016 Apr; 156(2):351-9. PubMed ID: 26968396
[TBL] [Abstract][Full Text] [Related]
18. Differential pharmacology and clinical utility of rolapitant in chemotherapy-induced nausea and vomiting.
Rapoport BL
Cancer Manag Res; 2017; 9():41-50. PubMed ID: 28260945
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review.
Tramèr MR; Carroll D; Campbell FA; Reynolds DJ; Moore RA; McQuay HJ
BMJ; 2001 Jul; 323(7303):16-21. PubMed ID: 11440936
[TBL] [Abstract][Full Text] [Related]
20. The Balance Between the Effectiveness and Safety for Chemotherapy-Induced Nausea and Vomiting of Different Doses of Olanzapine (10 mg Versus 5 mg): A Systematic Review and Meta-Analysis.
Wang DY; Chen Y; Zhang Y; Shen YQ
Front Oncol; 2021; 11():705866. PubMed ID: 34660273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
